Coya Therapeutics
NASDAQ: COYAHouston, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Coya Therapeutics
526 people in our graph share verified history with the Coya Therapeutics team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Fred Grossman · together at Johnson & Johnson (overlapped)
knows the team · via Harvard Business School
×4knows the team · via University of Michigan
×3knows the team · via Joan & Sanford I. Weill Medical College of Cornell University
knows the team · via Johnson & Johnson
knows the team · via AbbVie
Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
Founders & leadership
DS
David SnyderinCFO/COODavid Snyder is an executive with experience serving as CFO and COO across multiple life sciences, software, and manufacturing companies, ranging from startups to large enterprises. He has prepared five companies for IPO, led financial operations at five public companies, and has extensive experience with capital raising, M&A, and pharma partnerships.
FG
Fred GrossmaninPresident and Chief Medical OfficerFred Grossman held senior R&D and medical affairs roles across multiple pharmaceutical companies, overseeing clinical development, lifecycle management, and medical strategy for both branded and generic drugs spanning oncology, neuroscience, cell therapies, and cardiovascular/metabolic indications. He managed teams of 150-500 professionals and budgets exceeding $250 million in clinical development, portfolio management, and regulatory strategy.
HB
Howard BermaninFounder and Chief Executive Officer2020–2024Dr. Howard Berman holds a bachelor's degree in biology from the University of Michigan and a master's and Ph.D. in neuroscience and pharmacology from Weill Cornell Medical School. He is the founder of Coya Therapeutics, a clinical-stage biotechnology company developing regulatory T cell therapeutics, and serves as CEO and chairman of ReAlta Life Sciences with over 20 years of experience in entrepreneurship, technology transfer, and the life sciences industry.
AG
Andrea GoldsteinNamed on SEC filing
JT
Jani TuomiNamed on SEC filing
SM
Shawn M. TitcombNamed on SEC filing
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$56.9M disclosed across 4 of 7 rounds · 2020–2026
▶$10MraisedOct 2024 · 9 investors · BiotechnologyRule 506(b)
▶$10MraisedOct 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SnyderExecutive Officer
- Hideki GarrenDirector
- Anabella VillalobosDirector
- Dieter WeinandDirector
- Ann LeeDirector
- Fred GrossmanExecutive Officer
- Dov GoldsteinDirector
- Wilbur RossDirector
- Howard BermanExecutive Officer, Director
- Arun SwaminathanDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- Wilmington Capital Securities, LLC, Chardan Capital Markets LLC, BTIG, LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$26.5MraisedDec 2023 · 122 investors · BiotechnologyRule 506(b)
▶$26.5MraisedDec 2023 · 122 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dieter WeinandDirector
- Ann LeeDirector
- Wilbur RossDirector
- Fred GrossmanExecutive Officer
- Howard BermanExecutive Officer, Director
- Hideki GarrenDirector
- Dov GoldsteinDirector
- Anabella VillalobosDirector
- David SnyderExecutive Officer
- Offering amount
- $26.5M
- Amount sold
- $26.5M
- Placement agents
- BTIG, LLC, Newbridge Securities Corporation
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10.4MraisedMay 2022 · 45 investors · BiotechnologyRule 506(b)
▶$10.4MraisedMay 2022 · 45 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David SnyderExecutive Officer
- Anabella VillalobosDirector
- Dov GoldsteinDirector
- Adrian HepnerExecutive Officer
- Ann LeeDirector
- Howard BermanExecutive Officer, Director
- Hideki GarrenDirector
- Greg MacMichaelExecutive Officer
- Offering amount
- $20M
- Amount sold
- $10.4M
- Sales commissions
- $1.4M
- Placement agents
- Wilmington Capital Securities, LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10MraisedJan 2021 · 57 investors · BiotechnologyRule 506(b)
▶$10MraisedJan 2021 · 57 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Howard BermanExecutive Officer, Director
- Andrea GoldsteinExecutive Officer, Director
- Jani TuomiDirector
- Shawn M. TitcombDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- Shawn M. Titcomb
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$48.4Mvaluation at IPODec 2022 · $5.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlapBioworld74 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kite Pharma62 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Companies competing with Coya Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities?kalkinemedia.com · Aug 2026Frequently asked questions
- What does Coya Therapeutics do?
- Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.
- Who are Coya Therapeutics's investors?
- Coya Therapeutics's investors include Checkmate Capital Group LLC.
- How much funding has Coya Therapeutics raised?
- Coya Therapeutics has disclosed $56.9M raised across 4 of its 7 known rounds.
- Where is Coya Therapeutics headquartered?
- Coya Therapeutics is headquartered in Houston, US.